The Institute for Clinical and Economic Review, a non-profit institute evaluates the cost-effectiveness of drugs, medical devices, medical procedures, and diagnostics. The Institute for Clinical and Economic Review has published multiple assessments of healthcare technologies which provide a volume of evidence to better understand the quantitative conclusions by each evaluation…MORE
March 24, 2018 | Lopamudra Das, Brian Duffant, Courtney Coles
Chimeric Antigen Receptor T-cell (CAR-T) therapies represent a breakthrough in cancer care due to the significant clinical response induced in patients who do not respond to currently available treatments. In 2017, two CAR-T therapies were approved by the FDA –…MORE
Many life science manufacturers employ a payer size and control strategy in the US market. While this continues to be viable model, changes in formulary and benefit design result in local-level access variation. This suggests that alternative strategic approaches are important to consider when manufacturers engage in market access planning.
New drug coverage policies provide guidance around a payer’s coverage of new drugs in the time period between FDA approval and P&T committee review. As these policies proliferate, manufacturers may find initial new drug launch access to be more limited than anticipated.
Commercial and Medicare Part D payers…MORE
Payers who offer Medicare Part D plans may receive additional compensation after the point-of-sale. These funds are known as Direct & Indirect Remuneration (DIR), and account for growing levels of disparity between Part D gross and net drug costs. As DIR is primarily composed of manufacturer rebates on select drugs,…MORE
Recent PostsA Snapshot of the Conclusions on Long-term Value of Healthcare Treatments Conducted by the Institute for Clinical and Economic Review Group
CAR-T Commercial Market Access Brief – A Review of Initial Brand Access at Select US Payers
US Market Access – Key Considerations in a Changing Environment
Emerging Barriers to Launch Access – the Impact of New Drug Coverage Policies
Medicare Part D Direct & Indirect Remuneration